Clinical Scorecard: Comparison of Intranasal Dexmedetomidine and Oral Chloral Hydrate for Sedation During Transthoracic Echocardiography in Infants Under 3 Months with Congenital Heart Disease: A Retrospective Analysis

At a Glance

Key Highlights

• Higher initial sedation success rate with intranasal dexmedetomidine compared to oral chloral hydrate
• Shorter sedation onset and discharge times with dexmedetomidine
• No severe adverse reactions reported
• Low body weight and prolonged fasting time identified as risk factors for sedation success

Guideline-Based Recommendations

Diagnosis

• Evaluate infants with CHD for sedation needs prior to transthoracic echocardiography

Management

• Consider intranasal dexmedetomidine (2 μg/kg) as a preferred sedative for infants under 3 months

Monitoring & Follow-up

• Monitor heart rate and pulse oxygen saturation during sedation

Risks

• Be aware of independent risk factors such as low body weight and prolonged fasting time affecting sedation success

Patient & Prescribing Data

Infants under 3 months with congenital heart disease

Intranasal dexmedetomidine shows higher efficacy and safety compared to oral chloral hydrate

Clinical Best Practices

• Follow standard sedation procedures as per the Joint Committee for International Medical and Health Organization Accreditation
• Ensure minimum fasting of 2 hours prior to sedation
• Involve parents in the sedation plan and informed consent process

Related Resources & Content